Science Review <p style="line-height: 1.6;"><strong>Review articles</strong><br>p-ISSN: 2544-9346<br>e-ISSN: 2544-9443<br>DOI: 10.31435/rsglobal_sr<br>OCLC Number: 1036699169<br>Publisher - RS Global Sp. z O.O., Poland<br>Subject areas: engineering and medicine</p> en-US <p>All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.<br>CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.</p> (RS Global, Editorial office (journals department)) (Technical Support) Fri, 30 Jul 2021 00:00:00 +0200 OJS 60 INTERVAL EDGE COLORING OF TREES WITH STRICT RESTRICTIONS ON THE SPECTRUMS <p>An edge-coloring of a graph <em>G</em> with consecutive integers <em>C<sub>1 </sub>,..., C<sub>t</sub></em> is called an interval <em>t</em>-coloring if all the colors are used, and the colors of edges incident to any vertex of <em>G</em> are distinct and form an interval of integers. A graph <em>G</em> is interval colorable if it has an interval <em>t</em>-coloring for some positive integer <em>t</em>. For an edge coloring <em>a</em> and a vertex <em>v</em> the set of all the colors of the incident edges of <em>v</em> is called the spectrum of that vertex in <em>a</em> and is denoted by <em>Sa</em>(<em>v</em>). We consider the case where the spectrum for each vertex <em>v</em> is provided <em>S</em>(<em>v</em>), and the problem is to find an edge-coloring <em>a</em> such that for every vertex <em>v</em>, <em>Sa</em>(<em>v</em>)=<em>S</em>(<em>v</em>). We provide an <em>O</em>(<em>N</em>) algorithm that finds such an edge-coloring for trees that satisfies all the restrictions. If it is impossible to have an edge-coloring that satisfies the restrictions of the spectrums the algorithm will tell that too.</p> Albert Khachik Sahakyan Copyright (c) 2021 Albert Khachik Sahakyan Tue, 15 Jun 2021 00:00:00 +0200 PHARMACOTHERAPY OF SYSTEMIC AUTOIMMUNE DISEASES IN CONDITIONS OF THE COVID-19 PANDEMIC: INNOVATIVE EXPERIMENTAL STUDY <p>The article presents the results of an innovative experimental study of pharmacotherapy of systemic autoimmune diseases in a pandemic of coronavirus infection is a timely and socially oriented way. The methodology of conducting a content analysis based on the theoretical principles of pharmaceutical and medical law and its components. Author used the method of drug selection developed by the Department of Medical and Pharmaceutical Law, General and Clinical Pharmacy of the Kharkiv Medical Academy of Postgraduate Education. Content analysis was performed by dosage forms by grouping them using the Sturgess formula, followed by the construction of discrete series of variations and distribution polygon. Received data made possible to state, that in some circumstances, doctors have a choice of both drugs and dosage forms. However, the data obtained show a lack of balance between supply and demand for patients and physicians. The analysis allows to obtain a complete description of the balance of "supply and demand" between the range and types of dosage forms of drugs INN Silymarin ATC code A05BA03, that approved for use.</p> Ihor Hayduchok Copyright (c) 2021 Ihor Hayduchok Sat, 19 Jun 2021 00:00:00 +0200 PHARMACOLOGICAL VIEW ON THE PROBLEM OF COMORBIDITY IN THE PHARMACOTHERAPY OF CHRONIC PANCREATITIS <p>The article presents the results of the research concerning the pharmacotherapy of patients with chronic pancreatitis with comorbidity from the pharmacological view. During the study pharmacological approach to the problem of comorbidity among patients with chronic pancreatitis was analyzed. A survey among doctors and pharmacists was used during the research along with normative and legal, documentary, retrospective, bibliographic, systemic, forensic-pharmaceutical, sociological (questionnaire survey), comparative, graphic, mathematical analysis methods. The most common comorbid diseases that patients suffer from alongside with chronic pancreatitis were highlighted. Authors came to conclusion, that development of safe and affordable pharmaceutical therapy for patients with chronic pancreatitis and comorbidity is very important.</p> Iryna Tukhar, Viktoriya Shapovalova, Valentyn Shapovalov, Valeriy Shapovalov Copyright (c) 2021 Iryna Tukhar, Viktoriya Shapovalova, Valentyn Shapovalov, Valeriy Shapovalov Mon, 31 May 2021 00:00:00 +0200